Archemix and Isis Pharmaceuticals entered a broad intellectual property license agreement and research collaboration related to oligonucleotide-based therapeutics.
The transaction provides Archemix with access to approximately 400 issued and pending Isis patents covering chemistries, analytical methods, and manufacturing methods. The license agreement is for exclusive use with aptamer therapeutics. Archemix will research, develop, and commercialize the drugs based on its Selex technology.
Isis will receive milestones and royalties on aptamer therapeutics developed by Archemix that incorporate its chemistries or utilize its analytical or manufacturing methods. Additionally, Isis will receive a percentage of revenue generated by Archemix if this IP is sublicensed for the development of aptamer therapeutics. Isis also received a warrant to purchase an undisclosed number of shares of Archemix common stock.